Table 1.
Clinical Characteristics of Febrile Neutropenic Episodes in the Two Treatment Groups
| Clinical and hematologic parameters | PIP/TZO (n=59) | Ceftaz/Amikacin (n=59) | p-value |
|---|---|---|---|
| Age (year) | 5 (3-10) | 7 (5-10) | 0.215 |
| Gender: male | 33 (55.9%) | 35 (59.3%) | 0.709 |
| Weight (kg) | 17.5 (12.3-28.3) | 19.3 (15.0-35.0) | 0.074 |
| Peak temperature (◦C) | 38.9 (38.5-39.3) | 38.8 (38.4-39.2) | 0.724 |
| Time to needle (minute) | 30 (30-45) | 30 (30-55) | 0.697 |
| Hemoglobin (g/dl) | 8.8 (8.0-10.3) | 8.8 (7.7-9.8) | 0.636 |
| ANC (cells/cu.mm) | 129 (19-453) | 115 (10-582) | 0.802 |
| Platelet (x 1,000 cells/cu.mm) | 78 (26-181) | 54 (20-161) | 0.301 |
| CRP (mg/L) | 20.3 (11.0-51.2) | 18.4 (9.67-40.3) | 0.572 |
| Oral antibiotic prophylaxis | 39 (66.1%) | 40 (67.8%) | 0.845 |
| Oral antifungal prophylaxis | 13 (22.0%) | 8 (13.6%) | 0.229 |
| Underlying diseases | |||
| Acute lymphoblastic leukemia | 26 (44.1%) | 29 (49.2%) | |
| Acute myeloid leukemia | 5 (8.5%) | 5 (8.5%) | |
| Neuroblastoma | 5 (8.5%) | 4 (6.8%) | |
| Lymphoma | 4 (6.8%) | 4 (6.8%) | |
| Rhabdomyosarcoma | 4 (6.8%) | 4 (6.8%) | 0.923 |
PIP/TZO, Piperacillin/tazobactam; Ceftaz/Amikin, Ceftazidime plus amikacin; kg, kilogram; ◦C, degree Celsius; ANC, absolute neutrophil count; CRP, C-reactive protein